Tagged content

ObesityMeds

1 article

Label Update: FDA Requests Removal of Suicidal Ideation and Behavior Warning for GLP-1 Weight Management Drugs

FDA has requested that drug manufacturers remove suicidal ideation and behavior (SI/B) warnings from the labeling of three GLP-1 receptor agonist (GLP-1 RA) medications used for weight management:…

January 23, 2026

Ready to simplify your journey?

Talk to our experts and get tailored solutions to help you stay compliant and move forward with confidence.

Request Free Consultation

Submit RFI/RFP

No commitment required · 48h response time